Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Crizanlizumab · Adakveo, SEG-101

Monoclonal antibody · Antagonist of P-selectin (SELP) · developed by Novartis Pharms

Approved FDA, Nov 2019
NVS Developer

What is Crizanlizumab?

Crizanlizumab is a humanized IgG2 kappa monoclonal antibody that binds P-selectin on activated endothelium and platelets, blocking its interaction with PSGL-1 and other ligands. It can also dissociate preformed P-selectin/PSGL-1 complexes, which reduces adhesion between endothelial cells, platelets, red blood cells and leukocytes. It is studied in sickle cell disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Adakveo, SEG-101
Drug type
Monoclonal antibody
Targets
P-selectin (SELP), P-selectin glycoprotein ligand 1 (SELPLG) (binding partner it blocks)
Mechanism
Antagonist of P-selectin (SELP)
Pathways
P-selectin/PSGL-1 interaction, endothelial-platelet-leukocyte adhesion
Therapy area
Hematology
Developer
Novartis Pharms Corp (NVS)
FDA status
Approved as Adakveo (November 15, 2019), BLA761128 · FDA label
UNII
L7451S9126

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Sickle Cell Disease

More from Novartis Pharms

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Crizanlizumab

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.